Cyrano Therapeutics

Executive Summary

Cyrano Therapeutics is a clinical-stage biopharmaceutical company pioneering the first pharmaceutical therapy for persistent smell and taste loss, a condition that has become more prevalent since the COVID-19 pandemic. Based in Cambridge, Massachusetts, the company is advancing its lead candidate, CYR-064, an intranasal soft-mist spray designed to restore olfactory function through a regenerative medicine approach. Currently in Phase 2 clinical development, Cyrano addresses a significant unmet need with no approved treatments for this sensory dysfunction. The company's focus on a growing patient population and its differentiated mechanism of action position it as a potential first-in-class therapy. With limited public information, Cyrano operates as a private entity, suggesting that upcoming clinical data and strategic partnerships will be critical for its progression.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 Clinical Trial Results for CYR-06445% success
• Q4 2026Strategic Partnership or Licensing Deal40% success
• Q3 2026Series B Financing Round50% success